| Product Code: ETC8128234 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Malaysia Gastrointestinal Diseases Drug Development Market Overview |
3.1 Malaysia Country Macro Economic Indicators |
3.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, 2021 & 2031F |
3.3 Malaysia Gastrointestinal Diseases Drug Development Market - Industry Life Cycle |
3.4 Malaysia Gastrointestinal Diseases Drug Development Market - Porter's Five Forces |
3.5 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Molecular Targets, 2021 & 2031F |
3.7 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Marketed Drugs, 2021 & 2031F |
3.8 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Clinical Trials, 2021 & 2031F |
3.9 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Malaysia Gastrointestinal Diseases Drug Development Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastrointestinal diseases in Malaysia |
4.2.2 Growing awareness about the importance of early diagnosis and treatment of gastrointestinal diseases |
4.2.3 Technological advancements in drug development for gastrointestinal diseases in Malaysia |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in Malaysia |
4.3.2 High cost of drug development and clinical trials in the country |
5 Malaysia Gastrointestinal Diseases Drug Development Market Trends |
6 Malaysia Gastrointestinal Diseases Drug Development Market, By Types |
6.1 Malaysia Gastrointestinal Diseases Drug Development Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Gastroenteritis, 2021- 2031F |
6.1.4 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Inflammatory Bowel Disease (IBD), 2021- 2031F |
6.1.5 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Irritable Bowel Syndrome, 2021- 2031F |
6.1.6 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Malaysia Gastrointestinal Diseases Drug Development Market, By Molecular Targets |
6.2.1 Overview and Analysis |
6.2.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sodium Transporter NHE3 Inhibitor, 2021- 2031F |
6.2.3 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sphinogosine-1-Phosphate Receptor Functional Antagonist, 2021- 2031F |
6.2.4 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Tumor Necrosis Factor (TNF) Blocker, 2021- 2031F |
6.2.5 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Malaysia Gastrointestinal Diseases Drug Development Market, By Marketed Drugs |
6.3.1 Overview and Analysis |
6.3.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.3.3 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.3.4 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Mesalazine, 2021- 2031F |
6.3.5 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Malaysia Gastrointestinal Diseases Drug Development Market, By Clinical Trials |
6.4.1 Overview and Analysis |
6.4.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Etrolizumab, 2021- 2031F |
6.4.3 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By SHP647, 2021- 2031F |
6.4.4 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ABX464, 2021- 2031F |
6.4.5 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ASP3291, 2021- 2031F |
6.4.6 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Malaysia Gastrointestinal Diseases Drug Development Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Injectable, 2021- 2031F |
6.6 Malaysia Gastrointestinal Diseases Drug Development Market, By End-Users |
6.6.1 Overview and Analysis |
6.6.2 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 Malaysia Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
7 Malaysia Gastrointestinal Diseases Drug Development Market Import-Export Trade Statistics |
7.1 Malaysia Gastrointestinal Diseases Drug Development Market Export to Major Countries |
7.2 Malaysia Gastrointestinal Diseases Drug Development Market Imports from Major Countries |
8 Malaysia Gastrointestinal Diseases Drug Development Market Key Performance Indicators |
8.1 Number of clinical trials initiated for gastrointestinal diseases drugs in Malaysia |
8.2 Research and development (RD) expenditure on gastrointestinal diseases drug development in the country |
8.3 Number of partnerships and collaborations between local and international pharmaceutical companies in the field of gastrointestinal diseases drug development in Malaysia |
9 Malaysia Gastrointestinal Diseases Drug Development Market - Opportunity Assessment |
9.1 Malaysia Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Malaysia Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Molecular Targets, 2021 & 2031F |
9.3 Malaysia Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Marketed Drugs, 2021 & 2031F |
9.4 Malaysia Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Clinical Trials, 2021 & 2031F |
9.5 Malaysia Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Malaysia Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Malaysia Gastrointestinal Diseases Drug Development Market - Competitive Landscape |
10.1 Malaysia Gastrointestinal Diseases Drug Development Market Revenue Share, By Companies, 2024 |
10.2 Malaysia Gastrointestinal Diseases Drug Development Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here